Literature DB >> 10196291

Simultaneous infection with retroviruses pseudotyped with different envelope proteins bypasses viral receptor interference associated with colocalization of gp70 and target cells on fibronectin CH-296.

E C MacNeill1, H Hanenberg, K E Pollok, J C van der Loo, M F Bierhuizen, G Wagemaker, D A Williams.   

Abstract

Several factors are thought to limit the efficiency of retroviral transduction in clinical gene therapy protocols that target hematopoietic stem cells. For example, the level of expression of the amphotropic receptor Pit-2, a phosphate symporter, appears to be low in human and murine hematopoietic stem cells. We have previously demonstrated that transduction of hematopoietic cells in the presence of the fibronectin (FN) fragment CH-296 is extremely efficient (H. Hanenberg, X. L. Xiao, D. Dilloo, K. Hashino, I. Kato, and D. A. Williams, Nat. Med. 2:876-882, 1996). To examine functionally whether the retrovirus receptor is a limiting factor in transduction of hematopoietic cells, we performed competition experiments in the presence of FN CH-296 with retrovirus vectors pseudotyped with the same or a different envelope protein. We demonstrate in both human erythroleukemia (HEL) cells and primary human CD34(+) hematopoietic cells inhibition of efficient infection due to receptor interference when two vectors targeting the amphotropic receptor are used simultaneously. Receptor interference lasted up to 24 h. No interference was demonstrated when vectors targeting the amphotropic receptor and the gibbon ape leukemia virus (GALV) receptor Pit-1 were used concurrently. In contrast, simultaneous infection with vectors targeting both Pit-1 and Pit-2 yielded transduction efficiencies consistently higher than with either vector alone in both HEL cells and human CD34(+) hematopoietic cells. These data demonstrate that the use of FN CH-296 leads to amphotropic receptor saturation in these cells. Simultaneous infection with vectors targeting both amphotropic and GALV receptors may prove to be of additional benefit in the design of gene therapy protocols.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10196291      PMCID: PMC104174     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production.

Authors:  A D Miller; C Buttimore
Journal:  Mol Cell Biol       Date:  1986-08       Impact factor: 4.272

2.  Retrovirus packaging cells based on 10A1 murine leukemia virus for production of vectors that use multiple receptors for cell entry.

Authors:  A D Miller; F Chen
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

3.  Retroviral gene transduction of adult peripheral blood or marrow-derived CD34+ cells for six hours without growth factors or on autologous stroma does not improve marking efficiency assessed in vivo.

Authors:  R V Emmons; S Doren; J Zujewski; M Cottler-Fox; C S Carter; K Hines; J A O'Shaughnessy; S F Leitman; J J Greenblatt; K Cowan; C E Dunbar
Journal:  Blood       Date:  1997-06-01       Impact factor: 22.113

4.  Viral and cellular factors governing hamster cell infection by murine and gibbon ape leukemia viruses.

Authors:  C A Wilson; M V Eiden
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

5.  Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells.

Authors:  H Hanenberg; X L Xiao; D Dilloo; K Hashino; I Kato; D A Williams
Journal:  Nat Med       Date:  1996-08       Impact factor: 53.440

6.  Fibronectin improves transduction of reconstituting hematopoietic stem cells by retroviral vectors: evidence of direct viral binding to chymotryptic carboxy-terminal fragments.

Authors:  T Moritz; P Dutt; X Xiao; D Carstanjen; T Vik; H Hanenberg; D A Williams
Journal:  Blood       Date:  1996-08-01       Impact factor: 22.113

7.  Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy.

Authors:  A Larochelle; J Vormoor; H Hanenberg; J C Wang; M Bhatia; T Lapidot; T Moritz; B Murdoch; X L Xiao; I Kato; D A Williams; J E Dick
Journal:  Nat Med       Date:  1996-12       Impact factor: 53.440

8.  Retroviral-mediated gene transfer in human bone marrow cells growth in continuous perfusion culture vessels.

Authors:  P G Eipers; J C Krauss; B O Palsson; S G Emerson; R F Todd; M F Clarke
Journal:  Blood       Date:  1995-11-15       Impact factor: 22.113

9.  Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus.

Authors:  A D Miller; J V Garcia; N von Suhr; C M Lynch; C Wilson; M V Eiden
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

10.  Detection of receptor-specific murine leukemia virus binding to cells by immunofluorescence analysis.

Authors:  M J Kadan; S Sturm; W F Anderson; M A Eglitis
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

View more
  6 in total

1.  Determination of infectious retrovirus concentration from colony-forming assay with quantitative analysis.

Authors:  Young Jik Kwon; Gene Hung; W French Anderson; Ching-An Peng; Hong Yu
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

2.  Susceptibility of cell populations to transduction by retroviral vectors.

Authors:  Simon Wotherspoon; Alla Dolnikov; Geoff Symonds; Robert Nordon
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

3.  Optimizing siRNA efficacy through alteration in the target cell-adhesion substrate interaction.

Authors:  Sariah Khormaee; Omar A Ali; James Chodosh; David J Mooney
Journal:  J Biomed Mater Res A       Date:  2012-05-21       Impact factor: 4.396

4.  Evaluation of different protocols for gene transfer into non-obese diabetes/severe combined immunodeficiency disease mouse repopulating cells.

Authors:  Peter Ebeling; P Bach; U Sorg; A Schneider; T Trarbach; D Dilloo; H Hanenberg; S Niesert; S Seeber; T Moritz; M Flasshove
Journal:  J Cancer Res Clin Oncol       Date:  2006-10-20       Impact factor: 4.553

5.  Heparin inhibits retrovirus binding to fibronectin as well as retrovirus gene transfer on fibronectin fragments.

Authors:  D Carstanjen; P Dutt; T Moritz
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

6.  Retrovirus-associated heparan sulfate mediates immobilization and gene transfer on recombinant fibronectin.

Authors:  Pedro Lei; Bharat Bajaj; Stelios T Andreadis
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.